Literature DB >> 26260040

Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.

Joseph Gligorov1, Sandrine Richard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26260040     DOI： 10.1038/nrclinonc.2015.137

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.

Authors:  William J Gradishar; Dimitry Krasnojon; Sergey Cheporov; Anatoly N Makhson; Georgiy M Manikhas; Alicia Clawson; Paul Bhar; John R McGuire; Jose Iglesias
Journal:  Clin Breast Cancer       Date:  2012-06-23       Impact factor: 3.225

2.  Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Ann H Partridge; R Bryan Rumble; Lisa A Carey; Steven E Come; Nancy E Davidson; Angelo Di Leo; Julie Gralow; Gabriel N Hortobagyi; Beverly Moy; Douglas Yee; Shelley B Brundage; Michael A Danso; Maggie Wilcox; Ian E Smith
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

3.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

Authors:  Hope S Rugo; William T Barry; Alvaro Moreno-Aspitia; Alan P Lyss; Constance Cirrincione; Eleanor Leung; Erica L Mayer; Michael Naughton; Deborah Toppmeyer; Lisa A Carey; Edith A Perez; Clifford Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

Review 4.  Taxane-containing regimens for metastatic breast cancer.

Authors:  Davina Ghersi; Melina L Willson; Matthew Ming Ki Chan; John Simes; Emma Donoghue; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2015-06-10

5.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

Review 6.  Preclinical pharmacology of the taxanes: implications of the differences.

Authors:  Joseph Gligorov; Jean Pierre Lotz
Journal:  Oncologist       Date:  2004

7.  Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.

Authors:  J Bonneterre; H Roché; A Monnier; J P Guastalla; M Namer; P Fargeot; S Assadourian
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

8.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Ann Oncol       Date:  2014-09-18       Impact factor: 32.976

9.  A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

Authors:  Hope S Rugo; Mario Campone; Dino Amadori; Daniela Aldrighetti; Pierfranco Conte; Andrew Wardley; Cristian Villanueva; Michelle Melisko; M Brent McHenry; David Liu; Francis Lee; Xavier Pivot
Journal:  Breast Cancer Res Treat       Date:  2013-05-07       Impact factor: 4.872

10.  Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

Authors:  Linda T Vahdat; Agustin A Garcia; Charles Vogel; Christine Pellegrino; Deborah L Lindquist; Nicholas Iannotti; Prashanth Gopalakrishna; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2013-07-23       Impact factor: 4.872
  10 in total
  2 in total

1.  Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Carlo Angioni; Chul-Kyu Park; Sascha Meyer Dos Santos; Holger Jordan; Maria Kuzikov; Di Liu; Sebastian Zinn; Stephan W Hohman; Yannick Schreiber; Béla Zimmer; Mike Schmidt; Ruirui Lu; Jing Suo; Dong-Dong Zhang; Stephan M G Schäfer; Martine Hofmann; Ajay S Yekkirala; Natasja de Bruin; Michael J Parnham; Clifford J Woolf; Ru-Rong Ji; Klaus Scholich; Gerd Geisslinger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

2.  Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel.

Authors:  Cody W Lewis; Zhigang Jin; Dawn Macdonald; Wenya Wei; Xu Jing Qian; Won Shik Choi; Ruicen He; Xuejun Sun; Gordon Chan
Journal:  Oncotarget       Date:  2017-05-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.